Table 3 Changes in anxiety ratings over the course of 4 weeks of treatment with a high-cannabidiol (CBD) sublingual study product: autoregressive linear mixed models (Two-Tailed).

From: Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial

Clinical Scale

Mixed Model

Baseline n = 14 (ref.)

Week 1 n = 14

Week 2 n = 14

Week 3 n = 14

Week 4 n = 14

Baseline to Week 4

F p (ηp2)

Mean [95% CI]

Estimate (p) [95% CI]

Estimate (p) [95% CI]

Estimate (p) [95% CI]

Estimate (p) [95% CI]

Percent Change

Anxiety scales

       

Beck anxiety inventory (BAI)

17.48

<0.001 (0.65)

20.29

[16.31, 24.26]

−11.07 (<0.001) [−14.13, −8.02]

−13.00 (<0.001) [−16.96, −9.04]

−14.86 (<0.001) [−19.33, −10.38]

−16.21 (<0.001) [−21.03, −11.40]

−79.93%

Overall anxiety severity and impairment scale (OASIS)

24.80

<0.001 (0.75)

11.29

[9.93, 12.65]

−5.57 (<0.001) [−6.95, −4.19]

−6.21 (<0.001)

[−7.89, −4.54]

−7.00 (<0.001) [−8.80, −5.20]

−7.93 (<0.001)

[−9.79, −6.07]

−70.25%

Hamilton anxiety rating scale (HAM-A)

58.12

<0.001 (.84)

19.86

[17.68, 22.04]

−13.00 (<0.001) [−14.92, −11.08]

−13.64 (<0.001) [−16.06, −11.23]

−15.64 (<0.001) [−18.32, −12.97]

−16.43 (<0.001) [−19.25, −13.60]

−82.73%

State-trait anxiety inventory (STAI): state

4.97

0.002 (0.38)

46.00

[41.02, 50.98]

−6.71 (0.009) [−11.64, −1.79]

−11.50 (<0.001) [−17.51, −5.49]

−9.71 (0.004) [−16.22, −3.21]

−13.07 (<0.001) [−19.83, −6.32]

−28.42%

State-trait anxiety inventory (STAI): trait

10.65

<0.001 (0.67)

56.29

[51.78, 60.79]

−7.29 (<0.001) [−10.48, −4.09]

−11.36 (<0.001) [−15.55, −7.16]

−13.50 (<0.001) [−18.30, −8.70]

−15.79 (<0.001) [−21.00, −10.57]

−28.05%

  1. Bold numbers are significant at p ≤ 0.010 for 5 timepoints.
  2. Significance is only noted for estimates relative to the baseline reference group.
  3. Note: For the BAI, OASIS, HAM-A, and STAI, reduced estimates indicate clinical improvement.
Back to article page